Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zbigniew I Nowecki

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Cancer Research and Clinical Oncology|April 27, 2007
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)Piotr Rutkowski, Zbigniew I Nowecki, Maria Debiec-Rychter, et al.
Annals of Surgery|December 19, 2008
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodesAlexander C J van Akkooi, Zbigniew I Nowecki, Christiane Voit, et al.
BMC Cancer|December 1, 2009
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expressionJerzy Ostrowski, Marcin Polkowski, Agnieszka Paziewska, et al.
Annals of Surgical Oncology|May 3, 2007
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorPiotr Rutkowski, Zbigniew I Nowecki, Wanda Michej, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 31, 2007
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumorsPiotr Rutkowski, Maria Debiec-Rychter, Zbigniew I Nowecki, et al.
BMC Cancer|March 24, 2012
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution studyPiotr Rutkowski, Elżbieta Bylina, Anna Klimczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteriaAugustinus P T van der Ploeg, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Cancer Research and Clinical Oncology|April 27, 2007
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)Piotr Rutkowski, Zbigniew I Nowecki, Maria Debiec-Rychter, et al.
Annals of Surgery|December 19, 2008
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodesAlexander C J van Akkooi, Zbigniew I Nowecki, Christiane Voit, et al.
BMC Cancer|December 1, 2009
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expressionJerzy Ostrowski, Marcin Polkowski, Agnieszka Paziewska, et al.
Annals of Surgical Oncology|May 3, 2007
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorPiotr Rutkowski, Zbigniew I Nowecki, Wanda Michej, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|October 31, 2007
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumorsPiotr Rutkowski, Maria Debiec-Rychter, Zbigniew I Nowecki, et al.
BMC Cancer|March 24, 2012
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution studyPiotr Rutkowski, Elżbieta Bylina, Anna Klimczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteriaAugustinus P T van der Ploeg, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Pageof 3